DexCom
DXCM
861 hedge funds and large institutions have $47.7B invested in DexCom in 2022 Q1 according to their latest regulatory filings, with 77 funds opening new positions, 350 increasing their positions, 305 reducing their positions, and 140 closing their positions.
31% more funds holding in top 10
Funds holding in top 10: 13 → 17 (+4)
15% more repeat investments, than reductions
Existing positions increased: 350 | Existing positions reduced: 305
8.04% more ownership
Funds ownership: 381.32% → 389.37% (+8%)
4% less capital invested
Capital invested by funds: $49.5B → $47.7B (-$1.74B)
7% less funds holding
Funds holding: 930 → 861 (-69)
14% less call options, than puts
Call options by funds: $541M | Put options by funds: $626M
45% less first-time investments, than exits
New positions opened: 77 | Existing positions closed: 140
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$517M |
| 2 |
Sands Capital Management
Arlington,
Virginia
|
+$464M |
| 3 |
ClearBridge Investments
New York
|
+$434M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$257M |
| 5 |
AI
Alphabet Inc
Mountain View,
California
|
+$152M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$331M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$261M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$226M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$210M |
| 5 |
Two Sigma Investments
New York
|
-$149M |
DXCM Hedge Fund Activity: Q1 2022 in Review
861 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q1 2022, worth a combined $47.7B — down 3.5% from $49.5B a quarter earlier.
Sellers outnumbered buyers: 140 funds closed out of DXCM and 77 opened new positions — a net loss of 63 holders — while 305 trimmed existing stakes and 350 added.
The largest buyer was Jennison Associates, adding an estimated $517M. The largest seller was Fidelity Investments, cutting an estimated $331M.
- 861 institutional investors held DexCom (DXCM) as of Q1 2022, down from 930 in Q4 2021.
- Funds reported $47.7B of DexCom stock for Q1 2022, down 3.5% quarter-over-quarter.
- 77 funds opened new DexCom positions in Q1 2022 and 140 closed out, a net change of -63 holders.
- The largest DexCom buyer in Q1 2022 was Jennison Associates, an estimated $517M added.
- The largest DexCom seller in Q1 2022 was Fidelity Investments, an estimated $331M sold.
Based on aggregated 13F filings for Q1 2022.